Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Flexner

Showing results (61-70 of 137) with videos related to

Pageof 14
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2022
Transitioning Long-Acting Products to a Generic Marketplace: What's Missing?David H Brown Ripin, Kelly Catlin, Linda Lewis, et al.
Biomaterials Science|November 30, 2022
Antiviral supramolecular polymeric hydrogels by self-assembly of tenofovir-bearing peptide amphiphilesMaya K Monroe, Han Wang, Caleb F Anderson, et al.
Tetrahedron Letters|December 17, 2009
(3R, 9R, 10R)-Panaxytriol: A molecular-based nutraceutical with possible application to cancer prevention and treatmentFay Ng, Heedong Yun, Xiaoguang Lei, et al.
The Lancet. HIV|December 25, 2019
Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIVRobert C Bollinger, Chloe L Thio, Mark S Sulkowski, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 30, 2014
Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapyLu Zheng, Babafemi Taiwo, Rajesh T Gandhi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 18, 2018
Effect of Antiretroviral Therapy on Plasma Concentrations of Chloroquine and Desethyl-chloroquineMatthew M Ippolito, Jeffrey M Jacobson, Michael M Lederman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 7, 2007
Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavirPaul A Pham, Charles Flexner, Teresa Parsons, et al.
Clinical Pharmacokinetics|May 26, 2017
In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and AdolescentsRajith K R Rajoli, David J Back, Steve Rannard, et al.
Nanomedicine (London, England)|April 25, 2013
Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patientsJennifer Williams, Harlan R Sayles, Jane L Meza, et al.
Clinical Pharmacokinetics|December 20, 2014
Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIVRajith K R Rajoli, David J Back, Steve Rannard, et al.
Pageof 14

Showing results (61-70 of 137) with videos related to

Sort By:
Pageof 14
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2022
Transitioning Long-Acting Products to a Generic Marketplace: What's Missing?David H Brown Ripin, Kelly Catlin, Linda Lewis, et al.
Biomaterials Science|November 30, 2022
Antiviral supramolecular polymeric hydrogels by self-assembly of tenofovir-bearing peptide amphiphilesMaya K Monroe, Han Wang, Caleb F Anderson, et al.
Tetrahedron Letters|December 17, 2009
(3R, 9R, 10R)-Panaxytriol: A molecular-based nutraceutical with possible application to cancer prevention and treatmentFay Ng, Heedong Yun, Xiaoguang Lei, et al.
The Lancet. HIV|December 25, 2019
Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIVRobert C Bollinger, Chloe L Thio, Mark S Sulkowski, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 30, 2014
Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapyLu Zheng, Babafemi Taiwo, Rajesh T Gandhi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 18, 2018
Effect of Antiretroviral Therapy on Plasma Concentrations of Chloroquine and Desethyl-chloroquineMatthew M Ippolito, Jeffrey M Jacobson, Michael M Lederman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 7, 2007
Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavirPaul A Pham, Charles Flexner, Teresa Parsons, et al.
Clinical Pharmacokinetics|May 26, 2017
In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and AdolescentsRajith K R Rajoli, David J Back, Steve Rannard, et al.
Nanomedicine (London, England)|April 25, 2013
Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patientsJennifer Williams, Harlan R Sayles, Jane L Meza, et al.
Clinical Pharmacokinetics|December 20, 2014
Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIVRajith K R Rajoli, David J Back, Steve Rannard, et al.
Pageof 14